Trial Profile
A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs GM 1485 (Primary) ; Ubidecarenone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 01 Nov 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 02 Nov 2006 Results have been reported.
- 02 Oct 2005 New trial record.